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Advances in next-generation sequencing (NGS) technologies have enabled physi-
cians to test for genomic alterations in multiple cancer-related genes at once in
daily clinical practice. In April 2015, we introduced clinical sequencing using an
NGS-based multiplex gene assay (OncoPrime) certified by the Clinical Laboratory
Improvement Amendment. This assay covers the entire coding regions of 215
genes and the rearrangement of 17 frequently rearranged genes with clinical rel-
evance in human cancers. The principal indications for the assay were cancers of
unknown primary site, rare tumors, and any solid tumors that were refractory to
standard chemotherapy. A total of 85 patients underwent testing with multiplex
gene assay between April 2015 and July 2016. The most common solid tumor
types tested were pancreatic (n = 19; 22.4%), followed by biliary tract (n = 14;
16.5%), and tumors of unknown primary site (n = 13; 15.3%). Samples from 80
patients (94.1%) were successfully sequenced. The median turnaround time was
40 days (range, 18–70 days). Potentially actionable mutations were identified in
69 of 80 patients (86.3%) and were most commonly found in TP53 (46.3%), KRAS
(23.8%), APC (18.8%), STK11 (7.5%), and ATR (7.5%). Nine patients (13.0%)
received a subsequent therapy based on the NGS assay results. Implementation
of clinical sequencing using an NGS-based multiplex gene assay was feasible in
the clinical setting and identified potentially actionable mutations in more than
80% of patients. Current challenges are to incorporate this genomic information
into better therapeutic decision making.
W ith the paradigm shift to precision cancer medicine,there is a growing recognition that understanding of
genomic architecture enables the adoption of better therapeutic
strategies and that genotype-directed therapy can improve the
clinical outcomes of cancer patients.(1) In current clinical prac-
tice, hotspot-based, single-gene testing approaches, such as
those testing for EGFR mutations in non-small cell lung cancer
or RAS mutations in colorectal cancer, have commonly been
used.(2,3) However, several recent studies have reported that
more comprehensive characterization of genomic alterations is
necessary for successful identification of patients who may
benefit from molecularly targeted therapies, and could provide
more clinical benefits for individual patients.(4–8)
Recent technological innovations in next-generation sequenc-
ing (NGS) have facilitated comprehensive genomic profiling of
human cancers through whole-genome, whole-exome, and
whole-transcriptome sequencing, making it possible to deliver
genomically informed personalized cancer therapy to individ-
ual patients.(9–12) In particular, NGS-based multiplex gene
assays can analyze a large number of pre-selected genes with
clinical relevance to human cancers at once and are powerful
tools for the simultaneous screening of numerous cancer-
related genes in the clinical setting.
Clinical sequencing generally refers to sequencing of a gen-
ome or exome by NGS technologies for clinical applica-
tions.(13) To date, this approach has been adopted not only in
oncology but also in a variety of medical fields such as genetic
analysis of neurologic disorders or genetic phenotyping of
infectious diseases. In this study, we have defined clinical
sequencing as the characterization of the tumor genomic vari-
ants that may confer sensitivity to a specific molecularly tar-
geted therapy using an NGS-based multiplex gene assay.
In April 2015, we introduced clinical sequencing using an
NGS-based multiplex gene assay (OncoPrime) into daily
Cancer Sci | July 2017 | vol. 108 | no. 7 | 1440–1446 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attrib
ution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial
and no modifications or adaptations are made.
clinical practice.(14) We describe here the feasibility and diag-
nostic yield of the NGS assay in an initial cohort of patients
with advanced solid tumors.
Patients and Methods
Patient population. Between April 2015 and July 2016, 85
patients with histopathologically confirmed solid tumors under-
went an NGS-based multiplex gene assays (OncoPrime) at
Kyoto University Hospital. The principal indications for the
assay were cancers of unknown primary site, rare tumors, and
any solid tumors refractory to standard chemotherapy. This
study was approved by the Ethics Committee of the Kyoto
University Graduate School of Medicine (G692) and all
patients provided written informed consent for the use of geno-
mic and clinical data for research purposes.
NGS-based multiplex gene assay (OncoPrime). OncoPrime is
an NGS-based multiplex gene assay designed for clinical
tumor genomic analyses. This NGS assay can sequence the
entire coding region of 215 genes and concurrently examine
the rearrangement of 17 frequently rearranged genes with clini-
cal or preclinical relevance in human solid tumors (Table S1).
After the NGS assay was ordered by the treating physician,
5–10 slices of 10 lm sections of archival formalin-fixed paraf-
fin-embedded (FFPE) tumor tissue (tumor content ≥20%) or
DNA extracted from fresh frozen tumor tissue at our institu-
tion were shipped to a Clinical Laboratory Improvement
Amendment (CLIA)-certified laboratory of EA Genomics
(Morrisville, NC, USA). DNA extraction was performed by
EA Genomics. Solution hybridization targeted 3861 exons of
215 cancer-related genes and 59 introns of 17 genes commonly
rearranged in human cancers. Sequencing was performed on
an Illumina HiSeq 2500 machines (San Diego, CA, USA).
Variant calling was done using variant calling software (Var-
PROWL) in a CLIA-certified laboratory of EA Genomics.
The turnaround time (TAT) was defined as the period
between the date of ordering OncoPrime and that of receiving
NGS assay results by the treating physician.
Definition of actionability. Actionability implies that a protein
product of the mutated gene can impact clinical decision mak-
ing for patient treatment. The NGS-based multiplex gene assay
provides an enormous amount of information about genomic
alterations within tumors; however, sometimes it is challenging
to determine whether identified genomic alterations are action-
able or not.(15) In addition, the evidence behind actionability
ranges from sufficient clinical data to only preclinical evi-
dence, and several actionability classification schemes have
been proposed.(12,16–18)
In this study, we defined a genomic alteration as actionable
if the identified alterations met any of several criteria:
(1) It can be directly targeted by a United States Food and
Drug Administration (FDA)-approved drug (such as a
BRAF inhibitor targeting a BRAF mutation, an EGFR
inhibitor targeting an EGFR mutation, or an HER2 kinase
inhibitor targeting an HER2 mutation).
(2) It is a signaling pathway component that can be targeted by
an FDA-approved drug (such as a mammalian target of
rapamycin inhibitor for PIK3CA mutation, a smoothened
homolog inhibitor for the PTCH1 mutation, or a mitogen-
activated protein kinase kinase inhibitor for RAS mutation).
(3) It predicts treatment response to an FDA-approved drug
(such as a poly [ADP-ribose] polymerase inhibitor for
BRCA1/2 mutation).
(4) It can be targeted directly or indirectly by an investiga-
tional agent that is available in early clinical trials. For
instance, this category includes such genes as CTNNB1 or
TP53.
(5) It is a biomarker for which only preclinical data is avail-
able. For instance, this category includes such genes as
IGF2R or SMAD4.
Variant filtering and reporting. The procedure for variant pri-
oritization and filtering was as follows (Fig. S1). First, all
silent mutations in non-reference alleles were removed, keep-
ing mutations that were missense, nonsense, or involved splic-
ing junctions. Second, all non-reference alleles that appeared
in >1% of the population were removed, as these were likely
germline events. Third, all non-reference alleles with allele fre-
quencies <4% and >95% were removed, as these were below
the specified limit of detection of the assay and likely germline
events, respectively. Finally, the importance of variants was
prioritized based on membership in the following databases:
Online Mendelian Inheritance in Man (https://www.omim.org/
),(19) ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/),(20) Clini-
cal Trial.gov (https://clinicaltrials.gov/), Drug Bank (https://
www.drugbank.ca/), Catalogue of Somatic Mutations in Cancer
(http://cancer.sanger.ac.uk/cosmic),(21) and the Cancer Genome
Atlas (https://cancergenome.nih.gov/). NGS data were anno-
tated by N-of-One, Inc. (Concord, MA, USA). Genomic alter-
ations that were potentially targetable with an FDA-approved
drug or an investigational agent tested in early clinical trials
were reported as potentially actionable mutations. Including
variants of unknown significance, a maximum of 14 variants
was listed in a final report and returned to the treating physi-
cian.
Molecular tumor board. Our institutional molecular tumor
board comprises medical and surgical oncologists, pathologists,
bioinformaticians, and medical geneticists. The molecular
tumor board meetings are held for an hour every one or
2 weeks, and in general, 15–20 board members and clinicians
attend the meeting. The molecular tumor board discusses
genetically informed treatment options and other issues such
as the possibility of germline variants in two to three patients
and supports the treating physician for appropriate use of
sequencing data. T.K, M.K, Y.Y, M.K, M.N, E.N, H.M, S.M,
K.T, S.M, H.H, H.S, S.K, Y.O and M.M were the board mem-
bers.
Results
Patient characteristics. The patient characteristics are summa-
rized in Table 1. The median age was 58 years (range, 8–
82 years). Most patients (80.0%) had solid tumors refractory
to standard chemotherapy, and the remainder had cancers of
unknown primary site (15.3%) or rare tumors (4.8%). The
most common solid tumor types tested were pancreatic
(n = 19; 22.4%), followed by biliary tract (n = 14; 16.5%).
Feasibility of the NGS-based multiplex gene assay. Archival
FFPE tumor tissue was available for the NGS assay in 62
patients (Fig. 1). Because the remaining patients did not have
appropriate archival FFPE tumor tissue, they underwent endo-
scopic biopsy (n = 7), fine needle biopsy (n = 12), or exci-
sional biopsy (n = 4) of their primary or metastatic lesions.
DNA extracted from the archival FFPE tumor tissue or fresh
frozen tumor tissue was used for the NGS assay. The success
rate of the NGS assay was 82.3% (51 of 62 patients) when
using DNA extracted from archival FFPE tumor tissue,
whereas it was 95.7% (22 of 23 patients) when using DNA
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extracted from fresh frozen tumor tissue. In 12 of 85 patients
(14.1%), the initial NGS assay failed because of insufficient
tissue quantity (n = 3), failed library preparation (n = 4), or
high duplicate read rate (>80%) and/or low insert size
(<120 bp) (n = 5). Among these 12 patients, for six patients
from whom archival FFPE tumor tissue was used and one
patient from whom fresh frozen tumor tissue was used in the
first assay, the second NGS assay was successful when alterna-
tive DNA extracted from fresh frozen tumor tissue was used.
As a result, the NGS assay was successful for 80 patients
(94.1%) and the final report could be completed. In this group
of 80 patients, the median of DNA yield and concentration of
library DNA were 1853 ng (range, 125–31850) and 5.40 nM
(range, 0.20–36.93), respectively (Fig. S2). The mean depth
for sequencing reactions were analyzed in 58 patients, and its
median figure was 4397 (range, 2123–6674) (Fig. S3). The
median TAT was 40 days (range, 18–70) (Fig. S4).
Identification of potentially actionable mutations. Of the 80
patients with NGS success, at least one potentially actionable
mutation was identified in 69 patients (86.3%). The median
number of actionable mutations per patient was 2 (range, 0–6).
Potentially actionable mutations were identified throughout dif-
ferent tumor types and were most commonly found in TP53
(46.3%), KRAS (23.8%), APC (18.8%), STK11 (7.5%), and
ATR (7.5%) genes (Fig. 2, Table S2).
Therapeutic implications of actionable mutations. To explore
the impact of the NGS assay results on subsequent treatment
decision making, we classified the patients based on the avail-
ability of drugs suggested by genomic testing (Fig. 3). Forty-
two patients (60.9%) had genomic alterations that were poten-
tially targetable with an approved or off-label drug in Japan.
Nineteen patients (27.5%) had genomic alterations that were
not targetable with an approved or off-label drug in Japan, but
were targetable with an FDA-approved drug. Eight patients
(11.6%) had genomic alterations that were potentially tar-
getable with an investigational agent only available in early
clinical trials.
After the NGS assay, nine patients (13.0% of those with
actionable mutations) received subsequent therapy based on
the NGS assay results (Table 2). At the start of treatment
based on the NGS assay results, we discussed the therapeutic
indications and possible treatment options at our molecular
tumor board meeting. The doses and regimen schedules were
adjusted at the discretion of the treating physicians according
to the general condition of each patient. Six patients received
genotyped-directed therapy with molecularly targeted agents as
suggested by the NGS assay results. Notably, among these
patients, a patient with cancer of unknown primary site was
found to harbor an EGFR mutation, which had not been identi-
fied by conventional hotspot-based gene assays, most likely
because of low allele frequency. This patient was treated with
an EGFR tyrosine kinase inhibitor (erlotinib) and consequently
experienced a remarkable tumor response with improvement in
symptoms. Three patients with BRCA1 or BRCA2 mutations
did not receive genotype-directed therapy with molecularly tar-
geted agents, such as olaparib, because they were not approved
in Japan at that time. Instead, they received platinum-based
Table 1. Patient demographics and clinical characteristics








Cancers of unknown primary site 13 (15.3)
Rare tumors
Liposarcoma 1 (1.2)
Malignant schwannoma 1 (1.2)
Calcifying fibrous tumor 1 (1.2)
Thymic 1 (1.2)
Solid tumors refractory to standard chemotherapy
Pancreatic 19 (22.4)










Neuroendocrine tumor 1 (1.2)
Peritoneum 1 (1.2)
Uterine body 1 (1.2)
Fig. 1. Feasibility of the next-generation
sequencing (NGS)-based multiplex gene assay. NGS
success means that NGS was successfully completed,
and the treating physician could receive the NGS
assay results from the laboratory. Also, NGS failure
means that NGS was not successfully completed,
and the treating physician could not receive the
NGS assay results.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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therapies because these have been reported to elicit better
responses in these patients.(22–24)
Incidental findings. It is possible that the clinical NGS assay
incidentally revealed germline variants. With regard to these
incidental findings, the American College of Medical Genetics
and Genomics (ACMG) has published their recommendations
on the management of incidental germline findings from
somatic mutation profiling in the clinical setting.(25) Because
our gene panel contained 20 of 56 genes for which the ACMG
recommends return of pathogenic germline variants, we care-
fully reviewed whether the mutations found in these 20 genes
were derived from germline variants based on the patients’
personal and family histories of cancer and reported allele fre-
quencies. Pathogenicity was determined based on ClinVar and
gene-specific databases, such as Insight (https://www.insight-
group.org/), LOVD (http://www.lovd.nl/3.0/home), or the data-
base of the University of Utah Department of Pathology and
ARUP Laboratories (http://arup.utah.edu/database/BRCA/).
Consequently, among 80 patients with NGS success, five
patients (6.3%) had a suspected pathogenic germline variant in
at least one of the 20 genes: BRCA1 (n = 1), BRCA2 (n = 1),
TP53 (n = 2), and BRCA1 and TP53 (n = 1) (Table 3).
Patients 1 and 2 did not desire to undergo germline testing
because they considered that the result did not influence their
subsequent cancer treatment. By Sager sequencing using geno-
mic DNA extracted from peripheral lymphocytes, we con-
firmed that TP53 p.Gly245Asp in patient 3 and TP53
p.Arg175His in patient 5 were somatic variants and BRCA1
p.Gln934* in patient 5 was a germline variant. Patient 4 had
already been diagnosed with hereditary breast and ovarian can-
cer (HBOC) elsewhere.
Discussion
We reviewed our experience with the first consecutive 85
patients who underwent an NGS-based multiplex gene assay in















































Fig. 2. Heat map describing potentially actionable mutations identified in each patient. Each column represents one patient, and each row rep-
resents one gene. Potentially actionable mutations are shown in blue.
Fig. 3. Distribution of patients according to the availability of drugs
suggested by next-generation sequencing (NGS) assay results.
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of the NGS assay using clinical samples such as archival FFPE
or fresh frozen tumor tissue was 94.1%, supporting the feasi-
bility of clinical sequencing in the daily clinical practice.
In this study, most (86.3%) of the patients were found to
harbor at least one potentially actionable mutation. However,
the median TAT was 40 days (range, 18–70), which was not
satisfactory for a clinical setting because it caused delay in
treatment initiation. One of the main reasons for the long TAT
was long transport time because the NGS assay had to be per-
formed in a CLIA-certified laboratory in the United States. A
shorter TAT is an essential to promptly initiate cancer treat-
ment, especially for patients with advanced tumors refractory
to standard chemotherapy. Indeed, some patients unfortunately
missed the chance to receive a treatment based on the NGS
assay results because of the deterioration of their disease.
Therefore, shortening the TAT is very much required.
Several studies have reported that genomic information facil-
itates the adoption of better therapeutic strategies and that
genotype-directed therapy can improve the clinical outcomes
of cancer patients.(26) In fact, we observed notable treatment
response in a few patients. In this regard, rigorous studies are
needed to investigate whether genotype-directed therapy pro-
posed by comprehensive genomic profiling can result in better
clinical outcome in cancer patients. Several prospective studies
are now underway for verifying the clinical utility of compre-
hensive genomic profiling.(27,28)
The number of patients who could receive a therapy accord-
ing to NGS assay results was relatively limited (13.0% of
those with actionable mutations). In general, to receive geno-
type-directed therapy based on NGS assay results, it is neces-
sary to use an off-label drug or an investigational agent that is
available only in early clinical trials. However, in Japan, there
are several barriers, such as a high costs and statutory regula-
tions, to accessing these drugs in the clinic. Moreover, avail-
able clinical trials are open in limited institutions and for
selected patients, thus limiting patient enrollment. In accor-
dance with our experience, previous studies have also pointed
out these problems as obstacles to promoting precision medi-
cine in the field of cancer treatment.(29–31) To overcome these
problems, amendments of social rules and regulations would
be needed, to push the application of NGS assay from the
research setting into daily clinical practice.
Table 2. Patients who received subsequent therapy based on next-generation sequencing (NGS) assay results

















Everolimus Termination of treatment
before evaluation of
response due to poor
general condition
Wu et al.(42)
Biliary tract ERBB2 p.Ser310Phe
p.Gly660Asp
Afatinib Stable disease Sequist et al.(43), Suzawa et al.(44)
Biliary tract ERBB2 p.Gly776Arg Afatinib Discontinuation due to
adverse effects










response due to poor
general condition
Lowery et al.(22), Maxwell et al.(23),
Golan et al.(24)
Pancreatic BRCA2 p.Gln3026* S-1 plus oxaliplatin Partial response Lowery et al.(22), Maxwell et al.(23),
Golan et al.(24)
Liver BRCA1 p.Leu52Phe 5-FU plus cisplatin Termination of treatment
before evaluation of
response due to poor
general condition
Lowery et al.(22), Maxwell et al.(23),
Golan et al.(24)
5-FU, 5-fluorouracil.
Table 3. Patients with suspected pathogenic germline variants






1 44 M Pancreatic  BRCA2 p.Gln3026* –
2 78 F Colorectal  TP53 p.Arg273His –
3 57 M Colorectal  TP53 p.Gly245Asp Somatic
4 39 F Breast (HBOC) + BRCA1 p.Leu63* Germline
5 82 M Gastric  BRCA1 p.Gln934* Germline
TP53 p.Arg175His Somatic
HBOC, hereditary breast and ovarian cancer. †Patients 1 and 2 did not desire to undergo germline testing.
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With regard to incidental germline variants, we observed
five patients (6.3%) who had a suspected germline variant.
Sanger sequencing using genomic DNA showed that one
patient (patient 3) had a somatic variant of TP53 and one (pa-
tient 5) had somatic and germline variants of TP53 and
BRCA1, respectively. One patient with HBOC (patient 4) had
a confirmed germline variant of BRCA1. As for the remaining
two patients (patients 1 and 2), we provided detailed informa-
tion about the results to the patients and their families.
Although they understood the significance of germline testing,
they did not desire further testing because they considered the
results would not influence any subsequent cancer treatment.
Meric-Bernstam et al. recently reported that 4.3% patients who
underwent clinical NGS assays for advanced cancers probably
had pathogenic germline variants in one of 19 genes for which
the ACMG recommends return of pathogenic germline vari-
ants, with BRCA1, BRCA2, and TP53 being the most com-
mon.(32) Although there were a few limitations to the present
study such as the limited sample size and bias in the types of
tumor tested, we estimate that the frequency of incidental
germline variants in the Japanese population may be compara-
ble to or lower than in the series of Meric-Bernstam et al.
The analysis of the cancer genome using NGS provides
extensive information about the genomic alterations within
tumors. In this regard, molecular tumor boards play a pivotal
role in the appropriate understanding and clinical use of NGS
assay results.(33,34) In our institution, we regularly hold an
institutional multi-disciplinary molecular tumor board meetings
comprising medical oncologists, surgical oncologists, patholo-
gists, bioinformaticians, and medical geneticists, and discuss
possible treatment options based on NGS assay results and
other issues such as incidental findings.
In conclusion, the implementation of clinical sequencing
using an NGS-based multiplex gene assay is feasible in the
clinical setting. Although the clinical utility of comprehensive
genomic profiling has not yet been completely evaluated, we
believe that implementation of clinical sequencing using an
NGS-based multiplex gene assay would facilitate the rapid
molecular classification of tumors and has a great potential for
promoting precision cancer medicine.
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